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ABSTRACT Heart failure is one of the leading causes of hospitalization worldwide. Mitral regurgitation (MR)
is a known complication of end-stage cardiomyopathy and is associated with a poor prognosis due to
progressive mitral annular dilation. A vicious cycle of continuing volume overload, ventricular dilation, pro-
gression of annular dilation, increased LV wall tension, and worsening of MR and CHF occur. Commonly,
these patients were managed medically with diuretics and afterload reduction, and frequently with mi-
tral valve replacement, both of which have poor long term survival in patients with CHF and MR. Over a
10-year period we prospectively studied over 200 patients with cardiomyopathy and severe MR who un-
derwent mitral valve repair utilizing an undersizing overcorrecting annuloplasty ring. The mortality was
low with one intraoperative death and eight 30-day mortalities. There were 26 late deaths; 2 of these
patients had progression of heart failure and underwent transplantation. The 1-, 2-, and 5-year actuarial
survivals have been 82%, 71%, and 52%, respectively. The NYHA class has improved for all patients from
a preoperative mean of 3.2 ± 0.2 to 1.8 ± 0.4 postoperatively. All patients demonstrated improvement in
ejection fraction, cardiac output, and end diastolic volumes with a reduction in sphericity index and regur-
gitant volume at 2 years post operation. All of the observed changes contribute to reverse remodeling and
restoration of the normal left ventricular geometry. Mitral valve repair is a safe and effective operative in-
tervention that corrects MR and offers a new strategy for patients with MR and end-stage cardiomyopathy.
(J Card Surg 2004;19:396-400)
The management of patients with congestive heart
failure (CHF) is a worldwide heath care problem, and
a leading cause of hospitalization and mortality. De-
spite improvements in medical management, approx-
imately 50% of patients with severe CHF die within
3 years of presentation.1 In the United States alone,
nearly 4.9 million people are suffering from heart fail-
ure; however, less than 3000 of the 500,000 patients
diagnosed annually are offered transplantation due to
limitations of donor availability, comorbid medical con-
ditions, and often the advanced age of this patient pop-
ulation.2 Functional MR is a significant complication of
end-stage cardiomyopathy and may effect almost all
heart failure patients as a preterminal or terminal event.
Those with CHF and MR have a life expectancy of less
than 12 months.3 In an effort to resolve this problem
and deficiency, mitral valve reconstruction has evolved
as a surgical alternative to treat heart failure.
To address the issue of CHF and MR and its man-
agement, one needs to understand the anatomy of the
mitral valve. Mitral competence depends on the coor-
dinated function of the components of the mitral appa-
ratus: the leaflets, annulus, papillary muscles, chordae
tendinae, and the entire left ventricle (LV). Maintenance
of the chordal, annular, subvalvar continuity, and mitral
geometric relationships are important in the preserva-
tion of overall ventricular function; it may be even more
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important in patients with compromised function. As
the ventricle fails, the progressive dilatation of the LV
gives rise to MR. This action leads to a cycle of vol-
ume overload within an already dilated ventricle, pro-
gression of annular dilation, increased LV wall tension,
increased degrees of MR, and worsened CHF. Mitral
regurgitation is a significant complication of dilated car-
diomyopathy and end-stage heart disease, and the inci-
dence of MR complicating dilated cardiomyopathy has
been reported in as high as 60% of patients.4 Patients
with CHF and MR refractory to medical therapy have a
poor long-term survival, with only 46% 1-year survival
without transplantation.3 Furthermore, as little as 30 ml
of regurgitant volume in the setting of ischemic MR is
associated with only 47% 5-year survival.5
The functional MR that develops in CHF can be seen
in patients with either idiopathic or ischemic cardiomy-
opathy. In patients with nonischemic dilated cardiomy-
opathy, in the absence of intrinsic mitral valve disease
(i.e., myxomatous degeneration, calcific, or rheumatic
disease), MR is due to a progressive dilation of the
annular-ventricular apparatus with altered ventricular
geometry and a subsequent loss of leaflet coaptation
(Fig. 1).6,7 In patients with ischemic cardiomyopathy,
more complex mechanisms contribute to MR. The fail-
ure of leaflet coaptation may be related to a combi-
nation of dilation of the annular-ventricular apparatus
and LV wall/papillary muscle dysfunction. A large leaflet
area is required for coaptation because mitral leaflet
area is 21/2 times greater than the area of the mitral
orifice.8 There is a critical reduction in the tissue avail-
able for coaptation as more leaflet tissue is utilized
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Figure 1. The morphologic changes seen in heart failure. Shown on the left is the normal mitral apparatus and its effective zone
of coaptation (ZC), while changes that occur in heart failure are shown on the right. Theses alterations include myocardial thinning
and dilatation, blunting of the aorto-mitral angle, widening of the interpapillary distance, increased leaflet tethering, and decreased
leaflet-closing forces. This leads to altered force vectors on the papillary muscles (see insets). These morphologic changes combine
to result in loss of the zone of coaptation and central mitral regurgitation.
for the enlarging orifice. Eventually, the leaflet coap-
tation becomes ineffective and a central regurgitant
jet of functional insufficiency develops.9 Therefore, the
most significant determinant of mitral valve coaptation,
leaflet orifice area, and MR are the dimensions of the
mitral valve annulus. The LV dimension is less important
in functional MR because chordal and papillary muscle
length are not significantly altered in people with idio-
pathic cardiomyopathy with or without MR.6
In a recent study of patients with severe heart fail-
ure managed with pharmacologic agents (diuretics, ni-
trates, and afterload reduction agents), the observed
decrease in filling pressure and systemic vascular re-
sistance led to a reduction in the dynamic MR associ-
ated with their heart failure. This was attributed to a
reduction in the regurgitant orifice area related to the
decrease in LV volume and annular distension.10 This
complex relationship between mitral annular area and
leaflet coaptation may explain why, paradoxically, an un-
dersized “valvular” repair can help a myopathic “mus-
cular” problem.
Increases in LV preload, wall tension, diastolic vol-
ume, and stroke volume are all documented ventric-
ular adaptations to severe MR. There is a significant
decrease in the efficiency of the LV contraction and the
work expended by the LV, which produces flow that
ultimately does not contribute to effective forward car-
diac output. In these patients, maintenance of forward
flow becomes more difficult because up to 50% of
the stroke volume is ejected into the left atrium before
the aortic valve even opens.11 Eliminating the reversal
of flow or regurgitant volume alleviates the excessive
work place on the LV. In cases of severe myocardial
dysfunction, the positive effects of the elimination of
the regurgitant flow may be even more pronounced.
By utilizing mitral valve repair to restore the alterations
in the annular-ventricular unit, serves to not only re-
store valvular competency but also to improve ventric-
ular function.12-16
MANAGEMENT
For patients with cardiomyopathy and functional MR,
treatment of the underlying CHF with the use of di-
uretics, ACE-inhibitors, and beta blockers remains the
mainstay of medical management. Mitral valve replace-
ment has historically been the surgical approach to
patients with MR. However, little was understood of
the adverse consequences that interruption of the
annulus-papillary muscle continuity had on LV systolic
function.17 Ultimately, this method of mitral valve re-
placement in patients with heart failure was associated
with high mortality rates.18,19 In fact, it has been shown
that the mortality ascribed to these patients from mi-
tral valve replacement was due to the disruption of the
subvalvar apparatus and loss of LV function.20-23 Sev-
eral studies have demonstrated that preservation of the
annulus-papillary muscle continuity is of paramount im-
portance for the preservation of LV function.24,25 Pre-
serving the mitral valve apparatus and LV with mitral
valve repair has been demonstrated to enhance and
maintain LV function and geometry and decrease wall
stress.26,27 Therefore, maintaining the chordal, annu-
lar, and subvalvar continuity positively impacts mitral
geometric relationships and improves overall ventric-
ular function. It may prove most crucial in patients
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with compromised LV function. Mitral valve repair has
been shown to be safe with a significant decrease in
operative morbidity and mortality and good long-term
outcomes.
While surgically treating heart failure, it is important
to recall that the diameter of the mitral valve annulus is
the most significant determining factor of leaflet coap-
tation and MR.10 Utilizing the technique of undersiz-
ing and overcorrecting to repair the mitral valve serves
to restore the zone of coaptation (ZC) and permits its
effective application to patients with diminished heart
failure (Fig. 2). This would seem intuitive given the
fact that the left ventricular dimensions are of less im-
portance in functional MR wherein the length of the
chordae and papillary muscles are similar in myopathic
hearts regardless of the presence of MR. The degree
of LV dilation does not determine the degree of dilation
of the mitral ring because they are independent pro-
cesses. Furthermore, there is increased understanding
and knowledge of what happens to the left ventricular
unit of the mitral valve. We now know that the inter-
trigone distance is not fixed and does indeed dilate.28,29
These new findings assist us in the advancing surgical
Figure 2. Geometric mitral reconstruction. Successful aug-
mentation of the zone of coaptation and prevention of recur-
rent MR can be achieved by the placement of multiple annular
sutures followed by an undersized circumferential flexible an-
nuloplasty ring.
approaches to heart failure. As the distance between
the fibrous trigones is not stable and dilation occurs
along both the insertion of the posterior leaflet and in
the anterior portion, the role and applicability of under-
sizing and overcorrecting with a complete annuloplasty
ring is further classified.
Several technical points are worthy of mention. We
advocate the use of a circumferential ring, which re-
sults in a better distribution of forces. Additionally, nu-
merous sutures should be used to secure the ring. Do-
ing so will decrease the stress placed on each individual
suture. Because the beta receptors are down-regulated
in these patients due to beta overstimulation, we rou-
tinely use other means for inotropic support during
surgery. This includes the phosphodiesterase inhibitor
Milrinone used concomitantly with norepinephrine. Ad-
ditionally, Aprotinin is used for hemostasis.
The relative contraindications to this operation are
right ventricular failure, severely enlarged left ventric-
ular diameter and volumes, elevated pulmonary artery
pressures, extremely high norepinephrine levels, TNF,
and BNP. All of these are markers of long-term CHF.
Unfortunately, modalities of medical treatment that
included the use of recombinant agents directed at
TNF-α receptors and antiendothelin have failed to im-
prove treatment and outcome. There is a condition
when the technique of undersizing and overcorrect-
ing for MR in myopathic hearts may not have opti-
mal results. This is when there is asymmetrical left
ventricular geometry. Conceivably, the development of
new shaped rings could reverse these 3D geometrical
changes.
To date, at the University of Michigan (1994–2003),
over 200 patients with end-stage cardiomyopathy and
refractory MR have undergone mitral valve repair with
an undersized flexible annuloplasty ring. All patients
had NYHA Class III or IV heart failure despite receiving
maximal medical therapy including diuretics, nitrates,
afterload reduction agents, particularly ACE inhibitors,
and beta blockade. Patients had severe LV systolic dys-
function with a mean ejection fraction of 16 ± 5. Over-
all operative mortality was 5%. There have been eight
30-day mortalities: one intraoperative death due to right
ventricular failure, two from CHF, two from a cere-
brovascular bleed, and three succumbed to multisys-
tem organ failure. Five patients required IABP support,
and there were no patients who required the use of a LV
assist device. The mean duration of follow-up in these
patients was 49 months (range 1–74 months), with 1-,
2-, and 5-year actuarial survival of 82%, 71%, and 52%,
respectively. There have been 26 late deaths: 12 from
sudden ventricular arrhythmias, 8 from progression of
CHF without MR, 3 secondary to complications for
other operative procedures, 2 that progressed to trans-
plantation, and 1 from suicide.
The immediate postoperative echocardiograms
showed a mean transmitral gradient of 3 ± 1 mmHg
(range 2–6mmHg). At 7 years of follow-up, patients are
in NYHA Class I or II, with a mean ejection fraction of
26 ± 8. The NYHA Class improved for each patient and
all patients reported subjective improvement in func-
tional status. There was a demonstrated improvement
in LV ejection fraction (LVEF), cardiac output, and end-
diastolic volumes for all patients, with a reduction in
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sphericity index and regurgitant fraction. Although sig-
nificant undersizing of the mitral annulus was employed
to overcorrect for the ZC, no mitral stenosis was in-
duced and there was no evidence of systolic anterior
motion (SAM). This was most likely due to widening
of the aorto-mitral angle and increased LV size seen
in myopathic patients. In addition, acute remodeling of
the base of the heart from the undersizing of the mitral
annular ring may also contribute to the improvement
seen in these myopathic hearts. This may re-establish
the ellipsoid shape and somewhat normal geometry
to the base of the LV.12-15 These encouraging results
have been confirmed in several recent studies. Bitran
et al.30 noted a decrease in heart failure symptoms and
a decrease in New York Heart Association (NYHA) func-
tional class in 115 patients. In another report of 81 pa-
tients undergoing mitral valve surgery for mitral valve
regurgitation in dilated cardiomyopathy, LVEF improved
from 24% to 32% and there was an improvement in
NYHA class from 3.3 to 1.6. Survival in this study was
73%, 58%, and 38% at 1, 3, and 5 years, respectively.16
Finally, in a series of 44 patients who underwent iso-
lated mitral valve surgery, LVEF improved from 28% to
36% and NYHA functional class decreased from 2.9
to 1.2. Survival was 89%, 86%, and 67% at 1, 2, and
5 years, respectively. Furthermore, this study noted a
decrease in the left ventricular chamber sphericity.31
Interestingly, following the repair patients were able to
tolerate even higher does of medical therapy.
Further evidence of underlying mechanisms of why
mitral valve repair for patients with cardiomyopathy
may be successful is taken from a study of the coro-
nary flow characteristics in patients with MR, in the ab-
sence of coronary artery disease. This study assessed
coronary flow characteristics in patients before and af-
ter mitral valve reconstruction. Coronary flow reserve
was limited in patients with MR due to an increase in
baseline coronary flow and flow velocity, which was re-
lated to LV volume overload, hypertrophy, and preload
(LV wall stress). The restriction in coronary flow reserve
improved following mitral valve reconstruction because
of a reduction in the baseline coronary flow and flow
velocity, once the LV preload, work, and mass were
reduced.32 Based on this study in patients with MR
and cardiomyopathy, a restriction in the coronary flow
reserve would seem probable and an improvement in
flow reserve and velocity would be expected following
mitral valve repair. Ultimately mitral valve repair within
this setting leads to an improved LV geometry.
SUMMARY
The MR associated with end-stage heart failure is
thought to occur due to a progressive dilation of the
annular-ventricular apparatus, altered ventricular geom-
etry, loss of leaflet coaptation, and LV wall-papillary
muscle dysfunction. In this setting, medical manage-
ment alone may not be sufficient and the perceived
high morbidity and mortality of surgical interventions
associated with end-stage heart failure patients no
longer apply. Mitral valve repair with an annuloplasty
ring effectively corrects MR in cardiomyopathy pa-
tients. It is safe in this high-risk patient population, and
has acceptable operative mortality. The effects of this
procedure with severe myocardial dysfunction may be
attributed to a decrease in the regurgitant orifice area,
better effective forward flow, and an increase in coro-
nary flow reserve, all of which contribute to restoration
of the LV geometry. Combined with optimal medical
management, the treatment of end-stage heart fail-
ure can be expanded with results that approach that
of transplantation without the need for immunosup-
pression while decreasing the need for anticoagulation.
Thus, by restoring mitral competency and ventricular
geometry, mitral reconstruction offers expanded treat-
ment strategy for end-stage heart failure.
REFERENCES
1. Tavazzi L: Epidemiology of dilated cardiomyopathy: A still
undetermined entity. Eur Heart J 1997;18(1):4-6.
2. Hunt SA: Current status of cardiac transplantation. JAMA
1998;280(19):1692-1698.
3. Stevenson LW, Fowler MB, Schroeder JS, et al: Poor
survival of patients with idiopathic cardiomyopathy
considered too well for transplantation. Am J Med
1987;83(5):871-876.
4. Junker A, Thayssen P, Nielsen B, et al: The hemodynamic
and prognostic significance of echo-Doppler-proven mi-
tral regurgitation in patients with dilated cardiomyopathy.
Cardiology 1993;83(1-2):14-20.
5. Grigioni F, Enriquez-Sarano M, Zehr KJ, et al: Ischemic
mitral regurgitation: Long-term outcome and prognos-
tic implications with quantitative Doppler assessment.
Circulation 2001;103(13):1759-1764.
6. Boltwood CM, Tei C, Wong M, et al: Quantitative echocar-
diography of the mitral complex in dilated cardiomyopa-
thy: The mechanism of functional mitral regurgitation.
Circulation 1983;68(3):498-508.
7. Kono T, Sabbah HN, Rosman H, et al: Left ventricu-
lar shape is the primary determinant of functional mi-
tral regurgitation in heart failure. J Am Coll Cardiol
1992;20(7):1594-1598.
8. Hendren WG, Nemec JJ, Lytle BW, et al: Mitral valve
repair for ischemic mitral insufficiency. Ann Thorac Surg
1991;52(6):1246-1251 (discussion 1251-1252).
9. Chandraratna PA, Aronow WS: Mitral valve ring in nor-
mal vs dilated left ventricle. Cross-sectional echocardio-
graphic study. Chest 1981;79(2):151-154.
10. Rosario LB, Stevenson LW, Solomon SD, et al:. The mech-
anism of decrease in dynamic mitral regurgitation during
heart failure treatment: Importance of reduction in the re-
gurgitant orifice size. J Am Coll Cardiol 1998;32(7):1819-
1824.
11. Fann J, Ingels N, Miller D: Pathophysiology of mitral valve
disease and operative indications. In Edmunds L (ed):
Cardiac Surgery in the Adult. McGraw-Hill: New York,
1997, pp. 959-990.
12. Bach DS, Bolling SF: Early improvement in conges-
tive heart failure after correction of secondary mitral re-
gurgitation in end-stage cardiomyopathy. Am Heart J
1995;129(6):1165-1170.
13. Bolling SF, Deeb GM, Brunsting LA, et al: Early out-
come of mitral valve reconstruction in patients with
end-stage cardiomyopathy. J Thorac Cardiovasc Surg
1995;109(4):676-682 (discussion 682-683).
14. Bach DS, Bolling SF: Improvement following correction of
secondary mitral regurgitation in end-stage cardiomyopa-
thy with mitral annuloplasty. Am J Cardiol 1996;78(8):966-
969.
15. Bolling SF, Pagani FD, Deeb GM, et al: Intermediate-
term outcome of mitral reconstruction in cardiomyopathy.
400 ROMANO AND BOLLING J CARD SURG
UPDATE ON MITRAL REPAIR IN DILATED CARDIOMYOPATHY 2004;19:396-400
J Thorac Cardiovasc Surg 1998;115(2):381-386 (discus-
sion 387-388).
16. Chen FY, Adams DH, Aranki SF, et al: Mitral valve repair
in cardiomyopathy. Circulation 1998;98(19 Suppl):II124-
II127.
17. Pitarys CJ, II, Forman MB, Panayiotou H, et al: Long-term
effects of excision of the mitral apparatus on global and
regional ventricular function in humans. J Am Coll Cardiol
1990;15(3):557-563.
18. Pinson CW, Cobanoglu A, Metzdorff MT, et al: Late sur-
gical results for ischemic mitral regurgitation. Role of
wall motion score and severity of regurgitation. J Thorac
Cardiovasc Surg 1984;88(5 Pt 1):663-672.
19. Phillips HR, Levine FH, Carter JE, et al: Mitral valve re-
placement for isolated mitral regurgitation: Analysis of
clinical course and late postoperative left ventricular ejec-
tion fraction. Am J Cardiol 1981;48(4):647-654.
20. Gallino A, Jenni R, Hurni R, et al: Early results after mi-
tral valvuloplasty for pure mitral regurgitation. Eur Heart J
1987;8(8):902-905.
21. Rankin JS, Feneley MP, Hickey MS, et al: A clinical com-
parison of mitral valve repair versus valve replacement in
ischemic mitral regurgitation. J Thorac Cardiovasc Surg
1988;95(2):165-177.
22. Akins CW, Hilgenberg AD, Buckley MJ, et al: Mitral
valve reconstruction versus replacement for degenera-
tive or ischemic mitral regurgitation. Ann Thorac Surg
1994;58(3):668-675 (discussion 675-676).
23. Alvarez JM, Deal CW, Loveridge K, et al: Repairing the
degenerative mitral valve: Ten- to fifteen-year follow-up.
J Thorac Cardiovasc Surg 1996;112(2):238-247.
24. Sarris GE, Cahill PD, Hansen DE, et al: Restoration
of left ventricular systolic performance after reattach-
ment of the mitral chordae tendineae. The importance of
valvular-ventricular interaction. J Thorac Cardiovasc Surg
1988;95(6):969-979.
25. David TE, Uden DE, Strauss HD: The importance of the
mitral apparatus in left ventricular function after correction
of mitral regurgitation. Circulation 1983;68(3 Pt 2):II76-
II82.
26. Goldman ME, Mora F, Guarino T, et al: Mitral valvu-
loplasty is superior to valve replacement for preserva-
tion of left ventricular function: An intraoperative two-
dimensional echocardiographic study. J Am Coll Cardiol
1987;10(3):568-575.
27. Tischler MD, Cooper KA, Rowen M, et al: Mitral valve
replacement versus mitral valve repair. A Doppler and
quantitative stress echocardiographic study. Circulation
1994;89(1):132-137.
28. Hueb A, Jatene F, Moreira L, et al: Ventricular remodeling
and mitral valve modifications in dilated cardiomyopathy:
New insights from anatomic study. J Thorac Cardiovasc
Surg 2002;124(6):1216–1224.
29. McCarthy P: Does the intertrigonal distance dilate? Never
say never. J Thorac Cardiovasc Surg 2002;124(6):1078-
1079.
30. Bitran D, Merin O, Klutstein MW, et al: Mitral valve re-
pair in severe ischemic cardiomyopathy. J Card Surg
2001;16(1):79-82.
31. Bishay ES, McCarthy PM, Cosgrove DM, et al: Mitral valve
surgery in patients with severe left ventricular dysfunc-
tion. Eur J Cardiothorac Surg 2000;17(3):213-221.
32. Akasaka T, Yoshida K, Hozumi T, et al: Restricted coro-
nary flow reserve in patients with mitral regurgitation
improves after mitral reconstructive surgery. J Am Coll
Cardiol 1998;32(7):1923-1930.
